Hangzhou Innovative Chinese Medicine Standardization Research Institute Co., Ltd. announced a private placement of common shares for gross proceeds of CNY 6 million on October 28, 2020. The transaction will include participation from returning investor Sichuan Goldstone Asia Pharmaceutical Inc. (SZSE:300434) to retain its 100% stake in the company.